Renaissance Capital logo

I-Mab Priced, Nasdaq: IMAB

Late-stage cancer/autoimmune biotech developing in-licensed antibodies in China.

Industry: Health Care

Latest Trade: $13.68 0.00 (0.0%)

First Day Return: -10.7%

Return from IPO: -2.3%

Industry: Health Care

We are a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. We were founded to capture the opportunities presented by the confluence of two major developments: the emergence of an attractive and growing biologics market in China, and the revolutionary scientific breakthroughs in cancer and autoimmune disease medicines. We believe we are well-positioned to become a biotech leader in China because of our innovative discovery expertise, fit-for-purpose technology platforms, biomarker-enabled translational medicine capabilities, and clinical development capabilities. These integrated capabilities are further enhanced by our deep understanding of China’s biologics regulatory framework and our direct access to extensive pre-clinical and clinical trial resources in China. To date, we have developed an innovative pipeline of more than 10 clinical and pre-clinical stage assets through our internal research and development efforts and in-licensing arrangements with global pharmaceutical and biotech companies.
more less
IPO News for I-Mab
more
IPO Data
IPO File Date 10/29/2019
Offer Price $14.00
Price Range $12.00 - $15.00
Offer Shares (mm) 7.4
Deal Size ($mm) $104
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 01/16/2020
Offer Price $14.00
Price Range $12.00 - $15.00
Offer Shares (mm) 7.4
Deal Size ($mm) $104
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Shanghai, China
Founded 2014
Employees 185
Website www.i-mabbiopharma.com/en/